Floatz logo

ISOCYCLOPHOSPHAMIDE

B-Cell Acute Lymphoblastic Leukemia

Children's Oncology GroupSmall moleculePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
89/ 100

Competitive context

135 Active assets in the B-Cell Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
University of Washington
Phase 3BBB
Crisantaspase
City of Hope Medical Center
Phase 3BB
Vincristine sulfate
City of Hope Medical Center
Phase 3BB
Dasatinib
National Cancer Institute (NCI)
Phase 3BB
PEGASPARGASE
National Cancer Institute (NCI)
Phase 3BB

View all 50 →

Same molecule, other indications

ISOCYCLOPHOSPHAMIDE is also rated in:

angioimmunoblastic T-cell lymphomaDormant
BBB
Indicative · Phase 4
76 / 100
View asset →
primary mediastinal large B-cell lymphomaActive
BBB
Indicative · Phase 4
76 / 100
View asset →
B-cell non-Hodgkin lymphomaActive
BBB
Indicative · Phase 4
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →